NightWare Randomized Trial 02 (TNT/NW)
TNT/NW: Traumatic Nightmares Treated by NightWare (To Arouse Not Awaken)
Sponsor: Louis Stokes VA Medical Center
Listed as NCT04040387, this observational or N/A phase trial focuses on Combat Disorders and Nightmare and remains completed. Sponsored by Louis Stokes VA Medical Center, it has been updated 12 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)Nightmares are a common problem affecting 2-8% of the general population and a higher proportion of clinical populations. The negative consequences of untreated nightmares are significant and include impaired quality of life, sleep deprivation (often resulting in an increased intensity of nightmares), insomnia, daytime sleepiness, and fatigue. Untreated nightmares can also exacerbate the symptoms of underlying psychological dysfunction in people with depression and anxiety, leading to poor occupational and or social functioning. Nightmares can be idiopathic or associated with the use (or withdrawal) of certain medications or substances, or associated with disorders including PTSD. NightWare (Minneapolis, MN) has developed a novel approach to the treatment of nightmares. Through the use of a smartwatch-based application that senses physiologic parameters, the participant is aroused from sleep (without awakening the participant) so that the nightmare is interrupted prior to reaching a threshold of severity in which the participant would awaken in distress. Seconds later the participant returns to sleep without having experienced a nightmare. This approach avoids risk from pharmacological treatment, avoids exacerbation of symptoms from image rehearsal therapy and allows for a simple method with easily achieved adherence compared to existing treatments. The NightWare digital therapeutic system consists of a proprietary software...
Nightmares are a common problem affecting 2-8% of the general population and a higher proportion of clinical populations. The negative consequences of untreated nightmares are significant and include impaired quality of life, sleep deprivation (often resulting in an increased intensity of nightmares), insomnia, daytime sleepiness, and fatigue. Untreated nightmares can also exacerbate the symptoms of underlying psychological dysfunction in people with depression and anxiety, leading to poor occupational and or social functioning. Nightmares can be idiopathic or associated with the use (or withdrawal) of certain medications or substances, or associated with disorders including PTSD.
NightWare (Minneapolis, MN) has developed a novel approach to the treatment of nightmares. Through the use of a smartwatch-based application that senses physiologic parameters, the participant is aroused from sleep (without awakening the participant) so that the nightmare is interrupted prior to reaching a threshold of severity in which the participant would awaken in distress. Seconds later the participant returns to sleep without having experienced a nightmare. This approach avoids risk from pharmacological treatment, avoids exacerbation of symptoms from image rehearsal therapy and allows for a simple method with easily achieved adherence compared to existing treatments.
The NightWare digital therapeutic system consists of a proprietary software application installed on a smartwatch. The application has been effective in focus groups when used on both Apple smartwatches and Motorola smartwatches. For the purposes of this study, the investigators will be using only the Apple (Cupertino, CA) 3rd generation smartwatch and the Apple iPhone. The NightWare application uses physiological markers obtained via the smartwatch to determine by proprietary algorithm whether a participant is in the early stages of a nightmare, but has not yet awoken in distress. As directed by the algorithm, the smartwatch then applies varying degrees of vibratory stimulation to the wrist over variable lengths of time with the intention of arousing the participant from sleep without eliciting an awakening.
Status Flow
Change History
12 versions recorded-
Apr 16, 2026 — Present [daily]
Completed
Status: Unknown → Completed · Phase: NA → None
-
Jan 2026 — Apr 2026 [monthly]
Unknown NA
Status: Enrolling By Invitation → Unknown
-
Sep 2024 — Jan 2026 [monthly]
Enrolling By Invitation NA
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation NA
-
Dec 2023 — Jul 2024 [monthly]
Enrolling By Invitation NA
▶ Show 7 earlier versions
-
Mar 2023 — Dec 2023 [monthly]
Enrolling By Invitation NA
-
Jun 2021 — Mar 2023 [monthly]
Enrolling By Invitation NA
-
Apr 2021 — Jun 2021 [monthly]
Enrolling By Invitation NA
-
Jan 2021 — Apr 2021 [monthly]
Enrolling By Invitation NA
-
Oct 2020 — Jan 2021 [monthly]
Enrolling By Invitation NA
Status: Recruiting → Enrolling By Invitation
-
Feb 2020 — Oct 2020 [monthly]
Recruiting NA
-
Aug 2019 — Feb 2020 [monthly]
Recruiting NA
First recorded
Jul 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This study will provide preliminary estimates of safety and efficacy of the NightWare digital therapeutic system (iPhone + Apple watch + proprietary application) for the treatment of nightmare disorder associated with post-traumatic stress disorder (PTSD)-related sleep disturbance and the impact of improved sleep with the NightWare digital therapeutic system. The investigators hypothesize that the NightWare digital therapeutic system will significantly improve sleep quality in participants with PTSD-Related nightmares and poor sleep quality.
Contact Information
- Louis Stokes VA Medical Center
- Minneapolis Veterans Affairs Medical Center
- NightWare
- Ralph H. Johnson VA Medical Center
- Walter Reed National Military Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .